4th Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$800,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

4 issue areas, each in the filer's own words, with who lobbied on it and where.

Pharmacy PHA

Prescription Drug Costs. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. 180-Day Exclusivity. S.1114 - Expanding Access to Low-Cost Generics Act of 2023. H.R.3839/S.775: Increasing Transparency in Generic Drug Applications Act. Generic Drug Procurement Language as it Relates to H.R.2670/S.2226 - National Defense Authorization Act for Fiscal Year 2024. H.R.6109: Producing Incentives for Long-term Production of Lifesaving Supply of Medicines (PILLS) Act. Drug Shortages. H.R.10239/S.5368: End Drug Shortages Act. H.R. 3008/S.2362: Drug Shortage Prevention Act of 2023. S.2305: Biosimilar Red Tape Elimination Act. H.R.2880: Protecting Patients Against PBM Abuses Act. H.R.10545: American Relief Act, 2025 as it relates to Patent Thickets and Q1/Q2.

LobbyistCovered position, as disclosed
CRAIG BURTON —
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
JOHN MURPHY New —
KATHERINE RAAB —

Contacted: SENATE; HOUSE OF REPRESENTATIVES; Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS)

Bills named: H.R. 2670 (118th), H.R. 10239 (118th), S. 775 (118th), S. 2305 (118th), H.R. 6109 (118th), H.R. 2880 (118th), H.R. 3839 (118th), S. 2780 (118th), S. 2362 (118th), S. 2226 (118th), S. 1114 (118th), H.R. 3008 (118th), S. 5368 (118th), H.R. 10545 (118th), H.R. 5429 (118th)

Medicare/Medicaid MMM

Medicare Part D Reform. H.R.5461/S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act of 2023. H.R.1352/S.3934: Increasing Access to Biosimilars Act of 2023. Medicaid Generics Penalty.

LobbyistCovered position, as disclosed
CRAIG BURTON —
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
JOHN MURPHY New —
KATHERINE RAAB —

Contacted: Centers For Medicare and Medicaid Services (CMS); SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 5461 (118th), S. 2129 (118th), S. 3934 (118th), H.R. 1352 (118th)

Copyright/Patent/Trademark CPT

Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. H.R.4370/S.2220: Promoting and Respecting Economically Vital American Innovation Leadership (PREVAIL) Act. S.2140/H.R.9474: Patient Eligibility Restoration Act of 2023. H.R.6986/S.3583: To address patent thickets. H.R.5429/S.2780: Medication Affordability and Patent Integrity Act. H.R.9070/S.150: Affordable Prescriptions for Patients Act of 2024. S.142: Preserve Access to Affordable Generics and Biosimilars Act. S.5573: A bill to amend title 35, United States Code, to provide for a safe harbor from infringement of a method of use patent relating to drugs or biological products.

LobbyistCovered position, as disclosed
CRAIG BURTON —
KARIN HESSLER —
ILHAAM JAFFER —
PETER KELBEL —
JOHN MURPHY New —
KATHERINE RAAB —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: S. 3583 (118th), S. 2220 (118th), S. 142 (118th), S. 2140 (118th), H.R. 9070 (118th), H.R. 9474 (118th), S. 2780 (118th), S. 5573 (118th), S. 150 (118th), H.R. 4370 (118th), H.R. 6986 (118th), H.R. 5429 (118th)

Trade (domestic/foreign) TRD

General Trade Issues. Drug Supply Chain. Country of Origin Labeling.

LobbyistCovered position, as disclosed
KARIN HESSLER —
ILHAAM JAFFER —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.